DOCSLIB.ORG

( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0222392 A1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0222392 A1 0001US 20200222392A1 IN (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No .: US 2020/0222392 A1 Pollard et al. (43 ) Pub . Date : Jul. 16 , 2020 (54 ) COMPOUNDS USEFUL AS INHIBITORS OF (52 ) U.S. CI. ATR KINASE AND COMBINATION CPC A61K 31/496 ( 2013.01) ; A61K 31/4965 THERAPIES THEREOF (2013.01 ) ; A61K 31/497 ( 2013.01) ; C07D 413/04 ( 2013.01 ) ; A61K 33/24 ( 2013.01 ) ; (71 ) Applicant: Vertex Pharmaceuticals Incorporated , A61K 45/06 ( 2013.01) ; A61K 31/55 ( 2013.01) Boston , MA (US ) (57 ) ABSTRACT The present invention relates to compounds useful as inhibi ( 72 ) Inventors : John Robert Pollard , Abingdon (GB ) ; tors of ATR protein kinase and combination therapies Philip Michael Reaper, Abingdon thereof The invention also relates to pharmaceutically (GB ) ; Mohammed Asmal, Newton , acceptable compositions comprising the compounds of this MA (US ) invention ;methods of treating of various diseases, disorders , and conditions using the compounds of this invention ; ( 21) Appl. No .: 16 /507,139 processes for preparing the compounds of this invention ; intermediates for the preparation of the compounds of this ( 22 ) Filed : Jul. 10 , 2019 invention ; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and Related U.S. Application Data pathological phenomena ; the study of intracellular signal (60 ) Continuation of application No. 14 / 816,432 , filed on transduction pathways mediated by such kinases ; and the Aug. 3 , 2015 , now Pat . No. 10,478,430 , which is a comparative evaluation of new kinase inhibitors. division of application No. 13 /857,658 , filed on Apr. The compounds of this invention have formula I: 5 , 2013 , now abandoned . (60 ) Provisional application No.61 / 620,717 , filed on Apr. 5 , 2012 . NH2 Publication Classification (L )n - R N (51 ) Int. Ci. A61K 31/496 ( 2006.01 ) A61K 31/4965 ( 2006.01 ) A61K 31/497 (2006.01 ) ?R2 A61K 31/55 ( 2006.01 ) A61K 33/24 ( 2006.01) A61K 45/06 (2006.01 ) wherein the variables are as defined herein . CO7D 413/04 ( 2006.01 ) Specification includes a Sequence Listing. Patent Application Publication Jul. 16 , 2020 Sheet 1 of 18 US 2020/0222392 A1 uimarisha 2 FreeMonta99.9 ABT288-w 1 0,1 1FIGURE MDA-MB231ABT888CombinationwithVE821andIrradiation triglisering 2 VEAB 10 1 survival Melanogenic Patent Application Publication Jul. 16 , 2020 Sheet 2 of 18 US 2020/0222392 A1 ?? FIGURE1(continued) CombinationwithVE-821andIrradiationMDAMB231ABT888 .121012 TWD| Patent Application Publication Jul. 16 , 2020 Sheet 3 of 18 US 2020/0222392 A1 ABT 0.0005<*p DMSOVE-322A8-588+ wwwwwwwwwwwwwwww FIGURE2 OMSOVEABT-888 Patent Application Publication Jul. 16 , 2020 Sheet 4 of 18 US 2020/0222392 A1 r 0.05*** 4GY IB ??? survival Plogerne ** ABT DMSOVE-22ABT888 FIGURE2(continued) 2Gy OL ABT OGY BAX BUBU Patent Application Publication Jul. 16 , 2020 Sheet 5 of 18 US 2020/0222392 A1 FIGURE3 10 Patent Application Publication Jul. 16 , 2020 Sheet 6 of 18 US 2020/0222392 A1 Synergy/Antagonism 45 40 35 30 25 20 15 10 5 Rucaparib(UM) 1.3 90 0.3 0.2 FIGURE4 0.1 0.0 31.25 62.5 Cancer-selectivesynergisticeffectsofVE822withRucaparib 125 250 5007 VE-822 (UM) Patent Application Publication Jul. 16 , 2020 Sheet 7 of 18 US 2020/0222392 A1 SynergyAntagonism/ 40 35 30 ? ? -5 10.0 Rucaparib(UM) 5.0 2.5 1.3 0.3 0.2 FIGURE4(continued) 0.1 0.0 31.25 62.5 125 OSZ 009 VE-822 (wm) 1000 2000 juared uonezyddy iqnd ?uoge Jul. 16 , 2020 Sheet 8 of 18 US 2020/0222392 A1 SynergyAntagonism/ 30 å å då or -5 10.0 Rucaparib(UM) 5.0 2.5 1.3 0.6 0.3 0.2 FIGURE4(continued) 0.1 0.0 31.25 62.5 125 250 500 VE-822 (wm) 1000 2000 Patent Application Publication Jul. 16 , 2020 Sheet 9 of 18 US 2020/0222392 A1 SynergyAntagonism/ 40 35 30 i à 1008 10.0 Rucaparib(UM) 5.0 2.5 1.3 0.6 0.3 0.2 FIGURE4(continued) 0.1 0.0 31.25 62.5 125 OSZ 009 VE-822 (wm) 2000Loool juared uonezyddy iqnd ?uoge Jul. 16 , 2020 Sheet 10 of 18 US 2020/0222392 A1 AntagonismSynergy/ 40 35 30 å å å à or -5 10.0 Rucaparib(UM) 5.0 2.5 1.3 0.3 0.2 FIGURE4(continued) 0.1 0.0 31.25 62.5 125 250 500 VE-822 (wm) 1000 2000 juared uonezyddy iqnd ?uoge Jul. 16 , 2020 Sheet 11 of 18 US 2020/0222392 A1 SynergyAntagonism/ 40 35 30 ? ? ? ?? 10.0 Rucaparib(UM) 5.0 2.5 1.3 0.6 0.3 0.2 FIGURE4(continued) 0.1 0.0 31.25 62.5 125 250 500 VE822- (wm) 100012000 Patent Application Publication Jul. 16 , 2020 Sheet 12 of 18 US 2020/0222392 A1 SynergyAntagonism/ 40 35 30 25 20 uno? 0 o á 10.0 Rucaparib(UM) 5.0 2.5 1.3 0.3 0.2 FIGURE4(continued) 0.1 0.0 31.25 62.5 125 250 500 VE-822 (wm) 1000 2000 Patent Application Publication Jul. 16 , 2020 Sheet 13 of 18 US 2020/0222392 A1 2.00 VE-822UM)( 0.40 0.080 0.016 0.003 0.031 er FIGURE5 cellsCancerandNon-SynergisticwithRucaparibineffectsofVE822 0.125 0.50 Rucaparib(UM) 2.0 8.0 35.0 30.0 25.0 20.0 15.0 10.0 5.0 0.0 -5.0 ) % ( Synergy Patent Application Publication Jul. 16 , 2020 Sheet 14 of 18 US 2020/0222392 A1 2.00 VE-822 WT)( 0.40 0.080 0.016 0.003 0 0.031 FIGURE5(continued) 0.125 0.50 Rucaparib(UM) 2.0 8.0 35.0 30.0 25.0 20.0 15.0 10.0 5,0 0.0 -5.0 ) % ( Synergy Patent Application Publication Jul. 16 , 2020 Sheet 15 of 18 US 2020/0222392 A1 2.0 0.40 0.08 0.016 +2GYIR 0.0032 0.031 FIGURE6A 0.125 lonizingRadiationSynergisticeffectsofVE-822withRucapariband 0.50 2.0 Ruc(UM) 30.0 25.0 20.0 15.0 10.0 5.0 0.0 -5,0 -10.0 ) %( Synergy Patent Application Publication Jul. 16 , 2020 Sheet 16 of 18 US 2020/0222392 A1 2.0 0.08 0.016 +2GYIR 0.0032 0.031 FIGURE6A(continued) 0.125 0.50 2.0 Ruc(UM) 8.0 30.0 25.0 20.0 15.0 10.0 5,0 -5,0 -10.0 ) % ( Synergy Patent Application Publication Jul. 16 , 2020 Sheet 17 of 18 US 2020/0222392 A1 VE-822 (UM) 2.0 0.40 0.08 0.016 +BonMCis. 0.0032 0 0.031 FIGURE6B 0.125 0.50 SynergisticeffectsofVE-822withRucaparibandCisplatin Rucaparib(UM) 2.0 8.0 50.0 45.0 40.0 35.0 30.0 25.0 20.0 15.0 10.0 5.0 -5.0 -10.0 -15.0 ) % ( Synergy Patent Application Publication Jul. 16 , 2020 Sheet 18 of 18 US 2020/0222392 A1 VE-822 (WT) 2.0 0.40 0.08 80NMCis 0.016 0.0032 + 1800 FIGURE6B(continued) 0.125 0.50 Rucaparib(UM) 2.0 8.0 5,0 50.0 45.0 40,0 35.0 30.0 25.0 20.0 15.0 10.0 -5.0 -10.0 -15.0 ) %( Synergy US 2020/0222392 A1 Jul. 16 , 2020 1 COMPOUNDS USEFUL AS INHIBITORS OF SUMMARY OF THE INVENTION ATR KINASE AND COMBINATION [0008 ] The present invention relates to compounds useful THERAPIES THEREOF as inhibitors of ATR protein kinase . The invention also relates to pharmaceutically acceptable compositions com CROSS REFERENCE TO RELATED prising the compounds of this invention ; methods of treating APPLICATIONS of various diseases, disorders, and conditions using the compounds of this invention ; processes for preparing the [ 0001 ] This present invention claims the benefit, under 35 compounds of this invention ; intermediates for the prepa U.S.C. § 119 , of U.S. Provisional Application No. 61/620 , ration of the compounds of this invention ; and methods of 717 , filed Apr. 5 , 2012 , the entire contents of which are using the compounds in in vitro applications, such as the incorporated herein by reference . study of kinases in biological and pathological phenomena ; the study of intracellular signal transduction pathways medi BACKGROUND OF THE INVENTION ated by such kinases; and the comparative evaluation of new [ 0002 ] ATR ( “ ATM and Rad3 related ” ) kinase is a protein kinase inhibitors . kinase involved in cellular responses to DNA damage. ATR [0009 ] The compounds of the invention are very potent kinase acts with ATM (“ ataxia telangiectasia mutated ” ) ATR inhibitors . kinase and many other proteins to regulate a cell's response to DNA damage, commonly referred to as the DNA Damage BRIEF DESCRIPTION OF THE FIGURES Response (“ DDR ” ) . The DDR stimulates DNA repair, pro [0010 ) FIG . 1 : Clonogenic survival of cancer cells from motes survival and stalls cell cycle progression by activating MDA -MB - 231 breast cancer cell line when treated with cell cycle checkpoints , which provide time for repair. With VE - 821, ABT- 888 , and ionizing radiation out the DDR , cells are much more sensitive to DNA damage [0011 ] FIGS . 2 and 3 : Clonogenic survival of cancer cells and readily die from DNA lesions induced by endogenous from RKO and MDA -MB - 231 breast cancer cell line when cellular processes such as DNA replication or exogenous treated with VE - 822 , ABT- 888 , and ionizing radiation DNA damaging agents commonly used in cancer therapy. [0012 ] FIG . 4 : Cancer - selective synergistic effects for the [0003 ] Healthy cells can rely on a host of different proteins combination of VE - 822 with PARP inhibitor Rucaparib in for DNA repair including the DDR kinase ATR .
Load more

Recommended publications
  • Advances and Limitations of Antibody Drug Conjugates for Cancer
    biomedicines Review Advances and Limitations of Antibody Drug Conjugates for Cancer Candice Maria Mckertish and Veysel Kayser * Sydney School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; [email protected] * Correspondence: [email protected]; Tel.: +61-2-9351-3391 Abstract: The popularity of antibody drug conjugates (ADCs) has increased in recent years, mainly due to their unrivalled efficacy and specificity over chemotherapy agents. The success of the ADC is partly based on the stability and successful cleavage of selective linkers for the delivery of the payload. The current research focuses on overcoming intrinsic shortcomings that impact the successful devel- opment of ADCs. This review summarizes marketed and recently approved ADCs, compares the features of various linker designs and payloads commonly used for ADC conjugation, and outlines cancer specific ADCs that are currently in late-stage clinical trials for the treatment of cancer. In addition, it addresses the issues surrounding drug resistance and strategies to overcome resistance, the impact of a narrow therapeutic index on treatment outcomes, the impact of drug–antibody ratio (DAR) and hydrophobicity on ADC clearance and protein aggregation. Keywords: antibody drug conjugates; drug resistance; linkers; payloads; therapeutic index; target specific; ADC clearance; protein aggregation Citation: Mckertish, C.M.; Kayser, V. Advances and Limitations of Antibody Drug Conjugates for 1. Introduction Cancer. Biomedicines 2021, 9, 872. Conventional cancer therapy often entails a low therapeutic window and non-specificity https://doi.org/10.3390/ of chemotherapeutic agents that consequently affects normal cells with high mitotic rates biomedicines9080872 and provokes an array of adverse effects, and in some cases leads to drug resistance [1].
    [Show full text]
  • Synthesis of 4-Hydroperoxy Derivatives of Ifosfamide and Trofosfamide by Direct Ozonation and Preliminary Antitumor Evaluation in V/Vo
    [CANCER RESEARCH, 36, 2278-2281, July 1976] Synthesis of 4-Hydroperoxy Derivatives of Ifosfamide and Trofosfamide by Direct Ozonation and Preliminary Antitumor Evaluation in V/vo Hans-J. Hohorst, Gernot Peter, and Robert F. Struck Gustav-Embden-Zentrum der Biologischen Chemie, Abteilung KIr Zellchemie der J. W. Goethe-Universit~t, 6000 Frankfurt am Main, West Germany [H-J. H., G. P.], and Kettering-Meyer Laboratory, Southern Research Institute, Birmingham, Alabama 35205 [R. F. S.] SUMMARY reported routes (15, 17 to 19, 20), as well as to improve the yields. Two of us (11) have recently described such a syn- A one-step synthesis of 4-hydroperoxyifosfamide and 4- thesis of 4-hydroperoxycyclophosphamide, and application hydroperoxytrofosfamide is described. The method in- of this method to ifosfamide and trofosfamide and evalua- volves direct ozonation of ifosfamide and trofosfamide and tion of the products against leukemia L1210 in vivo are the offers improved yields in comparison with Fenton oxidation subjects of this report. The method is advantageous be- and greater convenience in comparison with ozonation of cause of its simplicity, its use of available starting materials, the appropriate 3-butenyl phosphorodiamidate. Evaluation the ease of isolation of products, and respectable yields. of the 4-hydroperoxy derivatives of cyclophosphamide, ifos- famide, and trofosfamide against leukemia L1210 in vivo suggests a superior effect for the ifosfamide derivative. MATERIALS AND METHODS Starting Materials. Cyclophosphamide, ifosfamide, and INTRODUCTION trofosfamide were obtained from Dr. Robert R. Engle, Drug Development Branch, National Cancer Institute, Silver Cyclophosphamide and its congeners ifosfamide and tro- Spring, Md., and from Asta Werke, 4800 Bielefeld, West fosfamide (1, 3) (Chart 1) are effective antitumor agents in Germany.
    [Show full text]
  • Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance
    cells Review Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance Ronay Cetin 1,† , Eva Quandt 2,† and Manuel Kaulich 1,3,4,* 1 Institute of Biochemistry II, Goethe University Frankfurt-Medical Faculty, University Hospital, 60590 Frankfurt am Main, Germany; [email protected] 2 Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, 08195 Barcelona, Spain; [email protected] 3 Frankfurt Cancer Institute, 60596 Frankfurt am Main, Germany 4 Cardio-Pulmonary Institute, 60590 Frankfurt am Main, Germany * Correspondence: [email protected]; Tel.: +49-(0)-69-6301-5450 † These authors contributed equally to this work. Abstract: Drug resistance is a commonly unavoidable consequence of cancer treatment that results in therapy failure and disease relapse. Intrinsic (pre-existing) or acquired resistance mechanisms can be drug-specific or be applicable to multiple drugs, resulting in multidrug resistance. The presence of drug resistance is, however, tightly coupled to changes in cellular homeostasis, which can lead to resistance-coupled vulnerabilities. Unbiased gene perturbations through RNAi and CRISPR technologies are invaluable tools to establish genotype-to-phenotype relationships at the genome scale. Moreover, their application to cancer cell lines can uncover new vulnerabilities that are associated with resistance mechanisms. Here, we discuss targeted and unbiased RNAi and CRISPR efforts in the discovery of drug resistance mechanisms by focusing on first-in-line chemotherapy and their enforced vulnerabilities, and we present a view forward on which measures should be taken to accelerate their clinical translation. Citation: Cetin, R.; Quandt, E.; Kaulich, M. Functional Genomics Keywords: chemotherapy resistance; cancer and drug vulnerabilities; functional genomics; RNAi Approaches to Elucidate Vulnerabilities of Intrinsic and and CRISPR screens Acquired Chemotherapy Resistance.
    [Show full text]
  • Combination Effects of Radiotherapy / Drug Treatments for Cancer Recommendation by the German Commission on Radiological Protection with Scientific Background
    Strahlenschutzkommission Geschäftsstelle der Strahlenschutzkommission Postfach 12 06 29 D-53048 Bonn http://www.ssk.de + Combination Effects of Radiotherapy / Drug Treatments for Cancer Recommendation by the German Commission on Radiological Protection with scientific Background Adopted at the 264th session of the SSK on 21 October 2013 Combination Effects of Radiotherapy / Drug Treatments for Cancer 2 The German original of this English translation was published in 2013 by the Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety under the title: Kombinationswirkungen Strahlentherapie/medikamentöse Tumortherapie Empfehlung der Strahlenschutzkommission mit wissenschaftlicher Begründung This translation is for informational purposes only, and is not a substitute for the official statement. The original version of the statement, published on www.ssk.de, is the only definitive and official version. Combination Effects of Radiotherapy / Drug Treatments for Cancer 3 Contents Preface ....................................................................................................................... 8 Recommendation ...................................................................................................... 9 Scientific background of the recommendation .................................................... 11 1 Introduction ..................................................................................................... 11 2 Drug licensing and pharmacovigilance .......................................................
    [Show full text]
  • Protocol of Clinical Study
    Protocol of clinical study Title Therapy-Optimization Trial and Phase II Study for the Treatment of Relapsed or Refractory of Primitive Neuroectodermal Brain Tumors and Ependymomas in Children and Adolescents Inclusion Criteria: Disease Characteristics • Histologically confirmed Medulloblastoma, cerebral PNET or Ependymoma • Refractory or relapsed disease • Measurable disease by MRI or detection of tumor cells in cerebrospinal fluid Patients characteristics • Performance status ECOG ≥ 3 or Karnofsky Status ≥ 40% • Life expectancy ≥ 8 weeks Hematological: • Absolute leukocyte count ≥ 2.0 x 10^9 /l • Hemoglobin ≥ 10g/dl • Platelet count ≥ 70 x 10^9/l Renal: • Creatinine no greater than 1.5 times UNL • No overt renal disease Hepatic: • Bilirubin less than 2.5 times UNL • AST and ALT less than 5 times UNL • No overt hepatic disease • Pulmonary: • No overt pulmonary disease • Cardiovascular: • No overt cardiovascular disease Other: • Not pregnant or nursing • Negative pregnancy test • Fertile patients must use effective contraception Orphanet Database. Clinical trial 2009. http://www.orpha.net/data/eth/DE/ID60629Eng.pdf • No uncontrolled infection Prior concurrent therapy • More than 2 weeks since prior systemic chemotherapy • More than 4 weeks since prior radiotherapy • No other concurrent anticancer or experimental drugs Examinations required • Examination of lumbar CSF • Cranial and spinal MRI within 14 days prior to start of treatment Intervention 1: P-HIT-REZ 2005: Active Comparator Carboplatine, Etoposide, Thiotepa, Trofosfamide intravenous chemotherapy 2: P-HIT-REZ 2005: Active Comparator Temozolomide, Etoposide, Thiotepa oral chemotherapy 3: E-HIT-REZ 2005: Experimental Temozolomide, Etoposide, Trofosfamide Phase II Intravent. Etoposide: Experimental Etoposide Phase II Number of expected inclusions 200 patients Study start February 2006 Estimated Study Completion January 2016 Study phase Phase II Phase III Study Design National, multicentre, treatment, randomized, crossover assignment, active control efficacy study Orphanet Database.
    [Show full text]
  • WO 2018/175958 Al 27 September 2018 (27.09.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/175958 Al 27 September 2018 (27.09.2018) W !P O PCT (51) International Patent Classification: A61K 31/53 (2006 .01) A61P 35/00 (2006 .0 1) C07D 251/40 (2006.01) (21) International Application Number: PCT/US20 18/024 134 (22) International Filing Date: 23 March 2018 (23.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/476,585 24 March 2017 (24.03.2017) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200 (US). (72) Inventors: NOMURA, Daniel, K.; 4532 Devenport Av enue, Berkeley, CA 94619 (US). ANDERSON, Kimberly, E.; 8 Marchant Court, Kensington, CA 94707 (US). (74) Agent: LEE, Joohee et al; Mintz Levin Cohn Ferris Glovsky And Popeo, P.C., One Financial Center, Boston, MA 021 11 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Ep 2569287 B1
    (19) TZZ _T (11) EP 2 569 287 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 413/04 (2006.01) C07D 239/46 (2006.01) 09.07.2014 Bulletin 2014/28 (86) International application number: (21) Application number: 11731562.2 PCT/US2011/036245 (22) Date of filing: 12.05.2011 (87) International publication number: WO 2011/143425 (17.11.2011 Gazette 2011/46) (54) COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERBINDUNGEN ALS HEMMER DER ATR-KINASE COMPOSÉS UTILISABLES EN TANT QU’INHIBITEURS DE LA KINASE ATR (84) Designated Contracting States: • VIRANI, Aniza, Nizarali AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Abingdon GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Oxfordshire OX144RY (GB) PL PT RO RS SE SI SK SM TR • REAPER, Philip, Michael Abingdon (30) Priority: 12.05.2010 US 333869 P Oxfordshire OX144RY (GB) (43) Date of publication of application: (74) Representative: Coles, Andrea Birgit et al 20.03.2013 Bulletin 2013/12 Kilburn & Strode LLP 20 Red Lion Street (73) Proprietor: Vertex Pharmaceuticals Inc. London WC1R 4PJ (GB) Boston, MA 02210 (US) (56) References cited: (72) Inventors: WO-A1-2010/054398 WO-A1-2010/071837 • CHARRIER, Jean-Damien Abingdon • C. A. HALL-JACKSON: "ATR is a caffeine- Oxfordshire OX144RY (GB) sensitive, DNA-activated protein kinase with a • DURRANT, Steven, John substrate specificity distinct from DNA-PK", Abingdon ONCOGENE, vol. 18, 1999, pages 6707-6713, Oxfordshire OX144RY (GB) XP002665425, cited in the application • KNEGTEL, Ronald, Marcellus Alphonsus Abingdon Oxfordshire OX144RY (GB) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Intravenous Ascorbate and Oncologic Agents
    © PAUL S. ANDERSON 2013 INTRAVENOUS ASCORBATE AND ONCOLOGIC AGENTS Updated Data Review and Policies for concurrent use at Anderson Medical Specialty Associates, Southwest College of Naturopathic Medicine Research Institute and Medical Center and Bastyr University Clinical Research Center Paul S. Anderson 05/01/2013 © Paul S. Anderson – All rights reserved – Reproduction and redistribution only allowed with proper attribution. Abstract: Intravenous application of ascorbic acid (IVAA) has a long history in adjunctive oncology communities. Its use has stimulated much debate regarding efficacy, safety and appropriate inclusion in oncologic practice. The potential for both antagonistic and synergistic interactions between IVAA and chemotherapies or radiation has existed for some time as an unanswered or confusing question in the naturopathic and allopathic oncology community. The purpose of this publication is to summarize and update the state of understanding of this complicated topic for clinicians employing either standard or integrative oncology care. INTRAVENOUS ASCORBATE AND ONCOLOGIC AGENTS Introduction: Intravenous ascorbate has been used in oncology practice by naturopathic and alternative allopathic physicians for decades. Published data regarding this therapy shows that it continues to be one of the most commonly employed alternative IV therapies. This popularity has both stimulated awareness of this therapy and concern regarding not only the safety and efficacy of IVAA in the oncology patient but also for the potential of antagonistic
    [Show full text]
  • Nephroblastoma High-Dose Chemotherapy with Autologous Stem Cell Rescue in Children with Nephroblastoma
    Bone Marrow Transplantation (2002) 30, 893–898 2002 Nature Publishing Group All rights reserved 0268–3369/02 $25.00 www.nature.com/bmt Nephroblastoma High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma B Kremens1, B Gruhn2, T Klingebiel13, C Hasan3, H-J Laws4, E Koscielniak12, B Hero5, B Selle6, C Niemeyer7, FG Finckenstein8, A Schulz9, A Wawer10, F Zintl2 and N Graf11 1Department of Pediatric Hematology/Oncology, University of Essen, Germany; 2Department of Pediatric Hematology/Oncology, University of Jena, Germany; 3Department of Pediatric Hematology/Oncology, University of Bonn, Germany; 4Department of Pediatric Hematology/Oncology, University of Du¨sseldorf, Germany; 5Department of Pediatric Hematology/Oncology, University of Cologne, Germany; 6Department of Pediatric Hematology/Oncology, University of Heidelberg, Germany, 7Department of Pediatric Hematology/Oncology, University of Freiburg, Germany; 8Department of Pediatric Hematology/Oncology, University of Hamburg, Germany; 9Department of Pediatric Hematology/Oncology, University of Ulm, Germany; 10Department of Pediatric Hematology/Oncology, University of Halle, Germany; 11Department of Pediatric Hematology/Oncology, University of Homburg/Saar, Germany; 12Department of Pediatric Hematology, Oncology and Immunology, Olga-Hospital, Stuttgart, Germany; and 13Department of Pediatric Hematology/Oncology, University of Frankfurt, Germany Summary: Keywords: Wilms tumor; high-dose chemotherapy; auto- logous bone marrow transplantation Children with Wilms tumor who have a particular risk of failure at relapse or at primary diagnosis were treated with high-dose chemotherapy (HDC) and auto- logous peripheral blood stem cell rescue in order to A child with newly diagnosed Wilms tumor (WT) has a improve their probability of survival. From April 1992 probability of about 85% of being cured with multimodal to December 1998, 23 evaluable patients received HDC treatment nowadays.
    [Show full text]
  • The Influence of Cell Cycle Regulation on Chemotherapy
    International Journal of Molecular Sciences Review The Influence of Cell Cycle Regulation on Chemotherapy Ying Sun 1, Yang Liu 1, Xiaoli Ma 2 and Hao Hu 1,* 1 Institute of Biomedical Materials and Engineering, College of Materials Science and Engineering, Qingdao University, Qingdao 266071, China; [email protected] (Y.S.); [email protected] (Y.L.) 2 Qingdao Institute of Measurement Technology, Qingdao 266000, China; [email protected] * Correspondence: [email protected] Abstract: Cell cycle regulation is orchestrated by a complex network of interactions between proteins, enzymes, cytokines, and cell cycle signaling pathways, and is vital for cell proliferation, growth, and repair. The occurrence, development, and metastasis of tumors are closely related to the cell cycle. Cell cycle regulation can be synergistic with chemotherapy in two aspects: inhibition or promotion. The sensitivity of tumor cells to chemotherapeutic drugs can be improved with the cooperation of cell cycle regulation strategies. This review presented the mechanism of the commonly used chemotherapeutic drugs and the effect of the cell cycle on tumorigenesis and development, and the interaction between chemotherapy and cell cycle regulation in cancer treatment was briefly introduced. The current collaborative strategies of chemotherapy and cell cycle regulation are discussed in detail. Finally, we outline the challenges and perspectives about the improvement of combination strategies for cancer therapy. Keywords: chemotherapy; cell cycle regulation; drug delivery systems; combination chemotherapy; cancer therapy Citation: Sun, Y.; Liu, Y.; Ma, X.; Hu, H. The Influence of Cell Cycle Regulation on Chemotherapy. Int. J. 1. Introduction Mol. Sci. 2021, 22, 6923. https:// Chemotherapy is currently one of the main methods of tumor treatment [1].
    [Show full text]
  • Cisplatin, Gemcitabine, and Treosulfan in Relapsed Stage IV Cutaneous Malignant Melanoma Patients
    British Journal of Cancer (2007) 97, 1329 – 1332 & 2007 Cancer Research UK All rights reserved 0007 – 0920/07 $30.00 www.bjcancer.com Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients *,1,2,3 1 1 2 J Atzpodien , K Terfloth , M Fluck and M Reitz 1 2 Fachklinik Hornheide an der Westfa¨lischen Wilhelms-Universita¨t Mu¨nster, Dorbaumstr. 300, Mu¨nster 48157, Germany; Europa¨isches Institut fu¨r Tumor Immunologie und Pra¨vention (EUTIP), Bad Honnef, Germany To evaluate the efficacy of cisplatin, gemcitabine, and treosulfan (CGT) in 91 patients with pretreated relapsed AJCC stage IV À2 cutaneous malignant melanoma. Patients in relapse after first-, second-, or third-line therapy received 40 mg m intravenous (i.v.) À2 À2 Clinical Studies cisplatin, 1000 mg m i.v. gemcitabine, and 2500 mg m i.v. treosulfan on days 1 and 8. Cisplatin, gemcitabine, and treosulfan therapy was repeated every 5 weeks until progression of disease occurred. A maximum of 11 CGT cycles (mean, two cycles) was administered per patient. Four patients (4%) showed a partial response; 15 (17%) patients had stable disease; and 72 (79%) patients progressed upon first re-evaluation. Overall survival of all 91 patients was 6 months (2-year survival rate, 7%). Patients with partial remission or stable disease exhibited a median overall survival of 11 months (2-year survival rate, 36%), while patients with disease progression upon first re-evaluation had a median overall survival of 5 months (2-year survival rate, 0%). Treatment with CGT was efficient in one-fifth of the pretreated relapsed stage IV melanoma patients achieving disease stabilisation or partial remission with prolonged but limited survival.
    [Show full text]
  • C19) United States 02) Patent Application Publication (10) Pub
    1111111111111111 IIIIII IIIII 111111111111111 111111111111111 IIIII IIIII IIIII 1111111111 11111111 US 20190241665Al c19) United States 02) Patent Application Publication (10) Pub. No.: US 2019/0241665 Al KREEGER et al. (43) Pub. Date: Aug. 8, 2019 (54) METHODS OF INHIBITING METASTASIS IN C07K 16/24 (2006.01) CANCER C12N 15/113 (2006.01) A61K 31/439 (2006.01) (71) Applicant: WISCONSIN ALUMNI RESEARCH (52) U.S. Cl. FOUNDATION, Madison, WI (US) CPC .......... C07K 1612854 (2013.01); A61P 35/04 (2018.01); C07K 16/24 (2013.01); Cl2N (72) Inventors: PAMELA KAY KREEGER, 2310/14 (2013.01); C12N 15/1138 (2013.01); MIDDLETON, WI (US); MOLLY A61K 31/439 (2013.01); C07K 2317/76 JANE CARROLL, MADISON, WI (2013.01); C07K 16/2866 (2013.01) (US); KAITLIN C. FOGG, FITCHBURG, WI (US) (57) ABSTRACT (21) Appl. No.: 16/256,065 As described herein, a method of inhibiting metastasis in (22) Filed: Jan. 24, 2019 cancer includes administering to a human subject diagnosed with a cancer of an organ of the peritoneal cavity a thera­ Related U.S. Application Data peutically effective amount of an inhibitor of CCR5 or P-selectin. Preferably the subject has a tumor positive for a (60) Provisional application No. 62/621,769, filed on Jan. ligand of P-selectin such as a CD24+ or PSGL-1 + tumor. 25, 2018. Analysis of samples from HGSOC patients confirmed increased MIP-1 fJ and P-selectin, suggesting that this novel Publication Classification multi-cellular mechanism can be targeted to slow or stop (51) Int. Cl. metastasis in cancers such as high-grade serous ovarian C07K 16/28 (2006.01) cancer, for example by using anti-CCR5 and P-selectin A61P 35/04 (2006.01) therapies developed for other indications.
    [Show full text]